{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:08Z","timestamp":1789824728304,"version":"4.0.1"},"reference-count":14,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Cerliponase alfa is currently the only approved disease-modifying therapy for neuronal ceroid lipofuscinosis type 2 (CLN2) disease and requires lifelong intracerebroventricular (ICV) infusion, traditionally via a scalp-sited ventricular access device (VAD). Chest-sited port (chest port) for intracerebroventricular access using a tunneled central venous access device is described as an alternative, though data remain limited. Methods: We present an anonymized caregiver narrative perspective describing two pediatric patients with CLN2 disease receiving cerliponase alfa infusions via different ICV access strategies: one patient who transitioned from a scalp-based ventricular access device to a chest port and one patient who initiated therapy with a chest port. A semi-structured caregiver interview was used to capture experiential insights related to decision-making, procedural burden, safety considerations, and psychosocial adaptation. Results: The caregiver identified key advantages of chest ports for ICV infusion, including durability of the device, enhanced securement, and smooth long-term routine integration. The transition from a scalp VAD to a chest port was described as proactive, well-coordinated, and associated with high caregiver satisfaction. Noted considerations included increased visibility of the access needle to the child, proximity to oral secretions, and potential misidentification of the port by emergency medical services. Families implemented mitigation strategies through labeling, education, and coordination with the care team. Conclusions: This caregiver-centered case report highlights how access device choice meaningfully shapes treatment burden, safety planning, and daily life for families managing CLN2 disease. As chest-port methodologies become adopted, incorporating caregiver and patient perspectives is essential to developing patient-centered treatment options for long-term intracerebroventricular therapy.<\/jats:p>","DOI":"10.3390\/children13030365","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:51:33Z","timestamp":1772614293000},"page":"365","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient and Family Perspective on Transition from Ventricular Access Device to Chest-Sited Port for Intracerebroventricular Infusion in CLN2 Disease"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3761-2751","authenticated-orcid":false,"given":"Mahie","family":"Gopalka","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"},{"name":"Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Votoupal","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-6637","authenticated-orcid":false,"given":"Sandi","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA"},{"name":"Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.277.5333.1802","article-title":"Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis","volume":"277","author":"Sleat","year":"1997","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1086\/302427","article-title":"Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder","volume":"64","author":"Sleat","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnen\/62.1.1","article-title":"The neuronal ceroid-lipofuscinoses","volume":"62","author":"Haltia","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mole, S., Williams, R., and Goebel, H. (2011). The Neuronal Ceroid Lipofuscinoses (Batten Disease), OUP.","DOI":"10.1093\/med\/9780199590018.001.0001"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-021-01813-5","article-title":"Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients","volume":"16","author":"Mole","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: An observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Schulz, A., Schwering, C., Wibbeler, E., Westermann, L.M., Hagenah, L., Lezius, S., Jha, A., Hunt, A., Slasor, P., and Reisewitz, P. (2025). Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1516026"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(23)00384-8","article-title":"Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): An open-label extension study","volume":"23","author":"Schulz","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/cts.13028","article-title":"Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease","volume":"14","author":"Hammon","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3171\/2021.7.PEDS21129","article-title":"A survival analysis of ventricular access devices for delivery of cerliponase alfa","volume":"29","author":"Craven","year":"2022","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of Intraventricular Cerliponase Alfa for CLN2 Disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/21678707.2020.1856654","article-title":"Cerliponase alfa for CLN2 disease, a promising therapy","volume":"8","author":"Aylward","year":"2020","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00381-025-06822-4","article-title":"Novel surgical approach for intraventricular cerliponase alfa enzyme replacement therapy via central venous access device (CVAD) port in neuronal ceroid lipofuscinosis type 2 (CLN2) disease","volume":"41","author":"Boop","year":"2025","journal-title":"Child\u2019s Nerv. Syst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3171\/2025.7.PEDS25222","article-title":"Chest-sited intraventricular access devices for cerliponase alfa infusion in Batten disease at a single tertiary United Kingdom pediatric center","volume":"37","author":"Read","year":"2025","journal-title":"J. Neurosurg. Pediatr."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/3\/365\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:32:26Z","timestamp":1772616746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/3\/365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["children13030365"],"URL":"https:\/\/doi.org\/10.3390\/children13030365","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}